<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615755</url>
  </required_header>
  <id_info>
    <org_study_id>HBOT_DFU</org_study_id>
    <nct_id>NCT03615755</nct_id>
  </id_info>
  <brief_title>Short Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine</brief_title>
  <official_title>A Pilot Study of Short Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine in Patient With Diabetic Foot Ulcer Wagner 3-4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hendry Irawan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Udayana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to evaluate the short duration HBOT can improve glycohemoglobin
      (HbA1c) levels, leukocyte count, and serum creatinine levels in patients with DFU (diabetic
      foot ulcer) Wagner 3-4.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study uses pretest and posttest control group design. All DM (diabetes mellitus)
      patients with DFU at Sanglah General Hospital, Denpasar who meet the inclusion and exclusion
      criteria and willing to follow the research procedure. All patients are signing the agreement
      paper after getting research explanation. All patients were briefed on the study research
      using HBOT. If the patients are willing to participate in the study and use HBOT was grouped
      to combination therapy, if the patients are willing to participate in the study but do not
      want to use HBOT was grouped to standard therapy, but if the patients are not willing
      participate then excluded.

      All patients were taken blood test for HbA1c levels, leukocyte count, and serum creatinine
      levels before debridement, then grouped for standard therapy or standard therapy with 10
      sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA (atmosphere absolute) for 90
      minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a
      week, so it takes two weeks. At the end of therapy, all blood tests were performed again in
      both groups.

      The inclusion criteria were patients who had type 2 diabetes and DFU Wagner class 3 or 4,
      aged over 18 years, and underwent debridement with or without toe amputation. The exclusion
      criteria were patients who had severe organs dysfunction such as heart failure, pulmonary
      infection, pneumothorax, chronic obstructive pulmonary disease, and stroke.

      Statistical analysis using SPSS 17.0 (SPSS Inc., Chicago, Illinois, USA). All variables were
      described before and after treatment. Analysis pretest and posttest values on both groups
      were used paired T-test and independent T-test. The statistical test results are significant
      if p &lt; 0.05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 27, 2016</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c levels</measure>
    <time_frame>2 weeks</time_frame>
    <description>HbA1c levels test before the patients were done debridement (baseline) and after 2 weeks therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leukocyte count</measure>
    <time_frame>2 weeks</time_frame>
    <description>Leukocyte count test before the patients were done debridement (baseline) and after 2 weeks therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>2 weeks</time_frame>
    <description>Serum creatinine levels test before the patients were done debridement (baseline) and after 2 weeks therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hyperbaric Oxygen Therapy</condition>
  <condition>Diabetic Foot Ulcer</condition>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Therapy (controlling blood sugar, antibiotic drug, ulcer debridement, wound care, offloading)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Therapy with adjuvant Hyperbaric Oxygen Therapy (Total 10 sessions, each session used pressure 2.4 ATA for 90 minutes per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperbaric Oxygen Therapy (HBOT)</intervention_name>
    <description>The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who had type 2 diabetes and DFU Wagner class 3 or 4, aged over 18 years, and
             underwent debridement with or without toe amputation.

        Exclusion Criteria:

          -  patients who had severe organs dysfunction such as heart failure, pulmonary infection,
             pneumothorax, chronic obstructive pulmonary disease, and stroke.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Kementerian Kesehatan Republik Indonesia. Diabetes Melitus Penyebab Kematian Nomor 6 di Dunia: Kemenkes Tawarkan Solusi Cerdik Melalui Posbind. (online) 2013 Sep. [cited 2016 Aug. 30] Available from: http://www.depkes.go.id/article/print/2383/diabetes-melitus-penyebab-kematian-nomor-6-di-dunia-kemenkes-tawarkan-solusi-cerdik-melalui-posbindu.html.</citation>
  </reference>
  <reference>
    <citation>World Health Organization. Global status report on noncommunicable diseases 2010. Switzerland: WHO Press; 2011.</citation>
  </reference>
  <reference>
    <citation>Société de Pathologie Infectieuse de Langue Française. Management of diabetic foot infections. Short text. Société de Pathologie Infectieuse de Langue Française. Med Mal Infect. 2007 Jan;37(1):1-25. English, French.</citation>
    <PMID>17357221</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. Global Report on Diabetes. Switzerland: WHO Press; 2016.</citation>
  </reference>
  <reference>
    <citation>Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV; American College of Foot and Ankle Surgeons. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006 Sep-Oct;45(5 Suppl):S1-66.</citation>
    <PMID>17280936</PMID>
  </reference>
  <reference>
    <citation>Wounds International. International Best Practice Guidelines: Wound Management in Diabetic Foot Ulcers. London: Wounds International A division of Schofield Healthcare Media Limited Enterprise House; 2013.</citation>
  </reference>
  <reference>
    <citation>Kessler L, Bilbault P, Ortéga F, Grasso C, Passemard R, Stephan D, Pinget M, Schneider F. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care. 2003 Aug;26(8):2378-82.</citation>
    <PMID>12882865</PMID>
  </reference>
  <reference>
    <citation>Waniczek D, Kozowicz A, Muc-Wierzgoń M, Kokot T, Swiętochowska E, Nowakowska-Zajdel E. Adjunct methods of the standard diabetic foot ulceration therapy. Evid Based Complement Alternat Med. 2013;2013:243568. doi: 10.1155/2013/243568. Epub 2013 Jun 13.</citation>
    <PMID>23843866</PMID>
  </reference>
  <reference>
    <citation>Jeffcoate WJ, Game FL. Evidence for the use of biological therapies in ulcers of the foot in diabetes. BioDrugs. 2014 Feb;28(1):1-6. doi: 10.1007/s40259-013-0052-3. Review.</citation>
    <PMID>23832595</PMID>
  </reference>
  <reference>
    <citation>Flood MS. Hyperbaric Oxygen Therapy for diabetic Foot Ulcers. The Journal of Lancaster General Hospital. 2007;2:140-145.</citation>
  </reference>
  <reference>
    <citation>Bhutani S, Vishwanath G. Hyperbaric oxygen and wound healing. Indian J Plast Surg. 2012 May;45(2):316-24. doi: 10.4103/0970-0358.101309.</citation>
    <PMID>23162231</PMID>
  </reference>
  <reference>
    <citation>Karadurmus N, Sahin M, Tasci C, Naharci I, Ozturk C, Ilbasmis S, Dulkadir Z, Sen A, Saglam K. Potential benefits of hyperbaric oxygen therapy on atherosclerosis and glycaemic control in patients with diabetic foot. Endokrynol Pol. 2010 May-Jun;61(3):275-9.</citation>
    <PMID>20602302</PMID>
  </reference>
  <reference>
    <citation>Aydin F, Kaya A, Karapinar L, Kumbaraci M, Imerci A, Karapinar H, Karakuzu C, Incesu M. IGF-1 Increases with Hyperbaric Oxygen Therapy and Promotes Wound Healing in Diabetic Foot Ulcers. J Diabetes Res. 2013;2013:567834. doi: 10.1155/2013/567834. Epub 2013 Feb 26.</citation>
    <PMID>23671876</PMID>
  </reference>
  <reference>
    <citation>El-Kader SMA, Ashmawy EM. Impact of Different Therapeutic Modalities on Healing of Diabetic Foot Ulcers. Eur J Gen Med. 2015;12:319-325.</citation>
  </reference>
  <reference>
    <citation>Gupta SK, Sharma AK. Effects of hyperbaric oxygen therapy on haematological and biochemical parameters. Ind J Aerospace Med. 2000;44:1-5.</citation>
  </reference>
  <reference>
    <citation>Al-Waili NS, Butler GJ, Beale J, Abdullah MS, Finkelstein M, Merrow M, Rivera R, Petrillo R, Carrey Z, Lee B, Allen M. Influences of hyperbaric oxygen on blood pressure, heart rate and blood glucose levels in patients with diabetes mellitus and hypertension. Arch Med Res. 2006 Nov;37(8):991-7.</citation>
    <PMID>17045116</PMID>
  </reference>
  <reference>
    <citation>Nwafor TS, Collins N. Managing low blood glucose levels in patients undergoing hyperbaric oxygen therapy. Ostomy Wound Manage. 2014 Apr;60(4):12-5.</citation>
    <PMID>24706399</PMID>
  </reference>
  <reference>
    <citation>Wilkinson D, Chapman IM, Heilbronn LK. Hyperbaric oxygen therapy improves peripheral insulin sensitivity in humans. Diabet Med. 2012 Aug;29(8):986-9. doi: 10.1111/j.1464-5491.2012.03587.x.</citation>
    <PMID>22269009</PMID>
  </reference>
  <reference>
    <citation>Irawan H, Kartika. Terapi Oksigen Hiperbarik sebagai Terapi Adjuvan Kaki Diabetik. Cermin Dunia Kedokteran-245. 2016;43:782-785.</citation>
  </reference>
  <reference>
    <citation>Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg. 2011 Jan;127 Suppl 1:131S-141S. doi: 10.1097/PRS.0b013e3181fbe2bf. Review.</citation>
    <PMID>21200283</PMID>
  </reference>
  <reference>
    <citation>Klein KC, Guha SC. Cutaneous wound healing: Current concepts and advances in wound care. Indian J Plast Surg. 2014 Sep-Dec;47(3):303-17. doi: 10.4103/0970-0358.146574.</citation>
    <PMID>25593414</PMID>
  </reference>
  <reference>
    <citation>Mathieu D, Wattel F. Physiologic Effects of Hyperbaric Oxygen on Microorganisms and Host Defences Against Infection. In: Mathieu D, editor. Handbook on Hyperbaric Medicine. Netherlands: Springer; 2006. p.103-119.</citation>
  </reference>
  <reference>
    <citation>Wibowo A. Oksigen Hiperbarik: Terapi Percepatan Penyembuhan Luka. JuKe Unila. 2015;5:124-128.</citation>
  </reference>
  <reference>
    <citation>Uzun G, Mutluoglu M, Uz O. Hyperbaric oxygen therapy in diabetic patients - comments on the paper by Karadurmus et al. Endokrynol Pol. 2011;62(3):286-7.</citation>
    <PMID>21717415</PMID>
  </reference>
  <reference>
    <citation>Fife CE, Buyukcakir C, Otto G, Sheffield P, Love T, Warriner R 3rd. Factors influencing the outcome of lower-extremity diabetic ulcers treated with hyperbaric oxygen therapy. Wound Repair Regen. 2007 May-Jun;15(3):322-31.</citation>
    <PMID>17537119</PMID>
  </reference>
  <reference>
    <citation>Kevin T. Pengaruh Terapi Oksigen Hiperbarik Terhadap eGFR berdasarkan Formula MDRD pada pasien Luka Kaki Diabetik (skripsi). Surabaya: Universitas Katolik Widya Mandala; 2015.</citation>
  </reference>
  <reference>
    <citation>Ayvaz S, Aksu B, Kanter M, Uzun H, Erboga M, Colak A, Basaran UN, Pul M. Preventive effects of hyperbaric oxygen treatment on glycerol-induced myoglobinuric acute renal failure in rats. J Mol Histol. 2012 Apr;43(2):161-70. doi: 10.1007/s10735-012-9391-5. Epub 2012 Feb 7.</citation>
    <PMID>22311626</PMID>
  </reference>
  <reference>
    <citation>Solmazgul E, Uzun G, Cermik H, Atasoyu EM, Aydinoz S, Yildiz S. Hyperbaric oxygen therapy attenuates renal ischemia/reperfusion injury in rats. Urol Int. 2007;78(1):82-5.</citation>
    <PMID>17192739</PMID>
  </reference>
  <reference>
    <citation>Migita H, Yoshitake S, Tange Y, Choijookhuu N, Hishikawa Y. Hyperbaric Oxygen Therapy Suppresses Apoptosis and Promotes Renal Tubular Regeneration After Renal Ischemia/Reperfusion Injury in Rats. Nephrourol Mon. 2016 Jan 17;8(1):e34421. doi: 10.5812/numonthly.34421. eCollection 2016 Jan.</citation>
    <PMID>26981502</PMID>
  </reference>
  <reference>
    <citation>Rubinstein I, Abassi Z, Milman F, Ovcharenko E, Coleman R, Winaver J, Better OS. Hyperbaric oxygen treatment improves GFR in rats with ischaemia/reperfusion renal injury: a possible role for the antioxidant/oxidant balance in the ischaemic kidney. Nephrol Dial Transplant. 2009 Feb;24(2):428-36. doi: 10.1093/ndt/gfn511. Epub 2008 Sep 17.</citation>
    <PMID>18799609</PMID>
  </reference>
  <reference>
    <citation>Berkovitch M, Tsadik R, Kozer E, Abu-Kishk I. The effect of hyperbaric oxygen therapy on kidneys in a rat model. ScientificWorldJournal. 2014;2014:105069. doi: 10.1155/2014/105069. Epub 2014 Aug 10.</citation>
    <PMID>25177712</PMID>
  </reference>
  <reference>
    <citation>Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014 Feb;18(1):1-14. doi: 10.4196/kjpp.2014.18.1.1. Epub 2014 Feb 13. Review.</citation>
    <PMID>24634591</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Udayana University</investigator_affiliation>
    <investigator_full_name>Hendry Irawan</investigator_full_name>
    <investigator_title>Clinical Research</investigator_title>
  </responsible_party>
  <keyword>Hyperbaric Oxygen Therapy</keyword>
  <keyword>Diabetic Foot Ulcer</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Leukocyte</keyword>
  <keyword>Serum creatinine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03615755/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03615755/SAP_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03615755/ICF_005.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

